The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study continues to address knowledge gaps in our understanding of type 1 diabetes and the effects of intensive therapy on its long-term complications.
The closing article in the series celebrating the 30th anniversary of Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/ EDIC) study reflects on how past investigations have shaped the study's future directions. The preceding articles on retinopathy, nephropathy, neuropathy, and cardiovascular disease have provided detailed updates on the state of the complications of diabetes in the cohort over the past 30 years. Collectively, the message is clear: chronic glycemia is the major modifiable factor driving the development and progression of the complications of type 1 diabetes (1-6). With intensive management of their diabetes, patients can achieve lower glycemia and reduce the risk of developing complications, including severe disease (7). In turn, patients free of complications report a good and sustained diabetes-related quality of life (8). The substantial effects of intensive therapy on primary prevention during DCCT, compounded by metabolic memory established during EDIC, make it imperative to intervene with intensive therapy as early after diagnosis as possible to effectively slow the course of complications.
As we move forward, the durability of our intervention will continue to be monitored: Will the effects of intensive therapydmetabolic memoryddecrease over time? EDIC will continue to monitor the trajectory of the development and progression of microvascular and cardiovascular disease. DCCT/EDIC core studies have been the foundation for many collaborations, each initiative advancing our understanding of the multisystem effects of diabetes and guiding future clinical and basic science investigations (Fig. 1) . In this spirit, several new ancillary studies are planned to investigate clinical topics across diverse fields, such as residual b-cell function, hearing dysfunction, and gastric disturbances.
RESEARCH DESIGN AND METHODS

Participant Retention
As reviewed previously, the DCCT interventional study was conducted between [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] [1990] [1991] [1992] [1993] , and since 1994 EDIC has continued as an observational follow-up of the consenting DCCT participants, comprising 95% of the surviving members of the original DCCT cohort (9,10). Retention during EDIC has been consistent (93-96%) whether considering original recruitment into primary prevention or secondary intervention groups or random assignment to intensive or conventional treatment. DCCT/EDIC ancillary studies are offered to all subjects, and compliance has routinely been .90% for studies involving minor procedures and/or questionnaires. Even with procedureintensive ancillary studies, such as the cardiac magnetic resonance imaging (MRI), participation rates were 81% or better (11). 1990-2005 2006-2013 Figure 1-The DCCT/EDIC core investigations have been the center of a diverse array of supplemental studies and collaborations over the past 30 years. The black circle denotes the major outcomes (i.e., retinopathy, nephropathy, neuropathy, and cardiovascular disease) studied during the DCCT (1983 DCCT ( -1993 and throughout EDIC (1994-present 
Additional Study Outcomes
In addition to the core data collection, the breadth of DCCT/EDIC investigations has been increased through supplemental studies proposed by the DCCT/EDIC Study Group and collaborations with experts in various fields of diabetes research (Fig. 1 
RESULTS
Metabolic Memory
As presented in the earlier accompanying manuscripts, the data through EDIC year 18 suggest that the beneficial risk reductions afforded by intensive relative to conventional therapy, while persistent and significant, are decreasing over time (30) (31) (32) (33) Based on pilot data obtained with 4-h mixed-meal tolerance tests on 58 DCCT/ EDIC subjects, mixed-meal tolerance tests are planned for the entire EDIC cohort. Three different ultrasensitive C-peptide assays will be used to provide comparative analyses of detection limits. The C-peptide results, in combination with the extensive, historical database, will extend our understanding of the relationship of long-term C-peptide production with HbA 1c levels over time, insulin dose requirements, hypoglycemia rates, and complications. Of importance, the study will also seek to identify the factors that mediate b-cell preservation and provide hope for future treatment options for type 1 diabetes.
A second initiative stems from the observation that hearing impairment is more common in type 2 diabetes than in the nondiabetic population (40,41). Early detection of hearing loss allows for earlier intervention, which preserves quality of life. The current proposal includes standardized hearing tests at all EDIC centers with oversight by a centralized audiology unit. The DCCT/ EDIC participants' nondiabetic partners/ spouses will be used as control subjects. 
